Rosuvastatin + Atorvastatin

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Metabolic Syndrome X

Conditions

Metabolic Syndrome X

Trial Timeline

Sep 1, 2006 → Jun 1, 2008

NCT ID

NCT00395486

About Rosuvastatin + Atorvastatin

Rosuvastatin + Atorvastatin is a approved stage product being developed by AstraZeneca for Metabolic Syndrome X. The current trial status is completed. This product is registered under clinical trial identifier NCT00395486. Target conditions include Metabolic Syndrome X.

What happened to similar drugs?

18 of 20 similar drugs in Metabolic Syndrome X were approved

Approved (18) Terminated (4) Active (2)

✅Telmisartan 40mg + Rosuvastatin 20mg + Telmisartan 80mg + Rosuvastatin 20mg + Telmisartan 40mg, 80 mg + Rosuvastatin 20mgYuhanApproved

✅Metformin + PlaceboEli LillyApproved

✅Henagliflozin 10 mg daily + Metformin 1700 mg dailyJiangsu Hengrui MedicineApproved

✅rosuvastatinAstraZenecaApproved

✅Simvastatin + Simvastatin/EzetimibeMerckApproved

✅Simvastatin + Vytorin + Placebo + EzetimibeMerckApproved

✅simvastatin + ezetimibe/simvastatinMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (13)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00683618	Phase 3	Completed	May 1, 2008	Jul 1, 2009	Hypercholesterolemia
NCT00620542	Phase 3	Completed	Jan 1, 2008	Jun 1, 2011	Coronary Atherosclerosis
NCT00427960	Approved	Terminated	Dec 1, 2006	Feb 1, 2008	Hypercholesterolaemia
NCT00395486	Approved	Completed	Sep 1, 2006	Jun 1, 2008	Metabolic Syndrome X
NCT00296400	Phase 2	Completed	Feb 1, 2006	Jun 1, 2009	Hyperlipidemia
NCT00296387	Phase 3	Completed	Jan 1, 2006	Oct 1, 2007	Acute Coronary Syndrome
NCT00329173	Phase 3	Completed	Nov 1, 2003	Aug 1, 2004	Hypercholesterolaemia
NCT00239330	Phase 3	Completed	Jun 1, 2003	Feb 1, 2005	Hypercholesteremia
NCT00653965	Phase 3	Completed	May 1, 2003	Feb 1, 2005	Hypercholesterolemia
NCT00653588	Phase 3	Completed	Apr 1, 2003	Sep 1, 2004	Hypercholesterolemia
NCT00654225	Phase 3	Completed	Oct 1, 2002	Mar 1, 2005	Hypercholesterolemia
NCT00654485	Phase 3	Completed	May 1, 2002	Feb 1, 2005	Metabolic Syndrome
NCT00653744	Phase 3	Completed	Mar 1, 2002	Mar 1, 2004	Hypercholesterolemia

Competing Products

20 competing products in Metabolic Syndrome X

See all competitors

Product	Company	Stage	Hype Score
Telmisartan 40mg + Rosuvastatin 20mg + Telmisartan 80mg + Rosuvastatin 20mg + Telmisartan 40mg, 80 mg + Rosuvastatin 20mg	Yuhan	Approved	35
Olmesartan medoxomil tablets low dose + Olmesartan medoxomil tablets high dose + Amlodipine	Daiichi Sankyo	Phase 3	40
olmesartan medoxomil + placebo + olmesartan medoxomil + olmesartan medoxomil	Daiichi Sankyo	Phase 3	40
14C-labeled YM178	Astellas Pharma	Phase 1	29
TRC150094	Torrent Pharmaceuticals	Phase 1/2	32
LY518674	Eli Lilly	Phase 2	35
Tirzepatide + Retatrutide + Placebo	Eli Lilly	Phase 3	47
Metformin + Placebo	Eli Lilly	Approved	43
Tirzepatide + Semaglutide	Eli Lilly	Pre-clinical	18
LY3849891 + Placebo	Eli Lilly	Phase 1	33
Henagliflozin 10 mg daily + Metformin 1700 mg daily	Jiangsu Hengrui Medicine	Approved	50
Rosuvastatin	AstraZeneca	Phase 3	40
AZD2693 + Placebo	AstraZeneca	Phase 1	29
Rosuvastatin	AstraZeneca	Phase 3	40
Rosuvastatin + Atorvastatin	AstraZeneca	Phase 3	40
rosuvastatin	AstraZeneca	Approved	43
Efinopegdutide	Merck	Phase 2	35
MK0767 + Comparator: fenofibrate + Comparator: Placebo (unspecified)	Merck	Phase 2	27
Vericiguat + Placebo	Merck	Phase 2	35
Metformin	Merck	Phase 2	35